Cargando…

Phosphate-control adherence in hemodialysis patients: current perspectives

OBJECTIVES: This review summarizes factors relevant for adherence to phosphate-control strategies in dialysis patients, and discusses interventions to overcome related challenges. METHODS: A literature search including the terms “phosphorus”, “phosphorus control”, “hemo-dialysis”, “phosphate binder...

Descripción completa

Detalles Bibliográficos
Autores principales: Umeukeje, Ebele M, Mixon, Amanda S, Cavanaugh, Kerri L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039061/
https://www.ncbi.nlm.nih.gov/pubmed/30013329
http://dx.doi.org/10.2147/PPA.S145648
_version_ 1783338621311385600
author Umeukeje, Ebele M
Mixon, Amanda S
Cavanaugh, Kerri L
author_facet Umeukeje, Ebele M
Mixon, Amanda S
Cavanaugh, Kerri L
author_sort Umeukeje, Ebele M
collection PubMed
description OBJECTIVES: This review summarizes factors relevant for adherence to phosphate-control strategies in dialysis patients, and discusses interventions to overcome related challenges. METHODS: A literature search including the terms “phosphorus”, “phosphorus control”, “hemo-dialysis”, “phosphate binder medications”, “phosphorus diet”, “adherence”, and “nonadherence” was undertaken using PubMed, PsycInfo, CINAHL, and Embase. RESULTS: Hyperphosphatemia is associated with cardiovascular and all-cause mortality in dialysis patients. Management of hyperphosphatemia depends on phosphate binder medication therapy, a low-phosphorus diet, and dialysis. Phosphate binder therapy is associated with a survival benefit. Dietary restriction is complex because of the need to maintain adequate protein intake and, alone, is insufficient for phosphorus control. Similarly, conventional hemodialysis alone is insufficient for phosphorus control due to the kinetics of dialytic phosphorus removal. Thus, all three treatment approaches are important contributors, with dietary restriction and dialysis as adjuncts to the requisite phosphate binder therapy. Phosphate-control adherence rates are suboptimal and are influenced directly by patient, provider, and phosphorus-control strategy-related factors. Psychosocial factors have been implicated as influential “drivers” of adherence behaviors in dialysis patients, and factors based on self-motivation associate directly with adherence behavior. Higher-risk subgroups of nonadherent patients include younger dialysis patients and non-whites. Provider attitudes may be important – yet unaddressed – determinants of adherence behaviors of dialysis patients. CONCLUSION: Adherence to phosphate binders, low-phosphorus diet, and dialysis prescription is suboptimal. Multicomponent strategies that concurrently address therapy-related factors such as side effects, patient factors targeting self-motivation, and provider factors to improve attitudes and delivery of culturally sensitive care show the most promise for long-term control of phosphorus levels. Moreover, it will be important to identify patients at highest risk for lack of control, and for programs to be ready to deliver flexible person-centered strategies through training and dedicated resources to align with the needs of all patients.
format Online
Article
Text
id pubmed-6039061
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60390612018-07-16 Phosphate-control adherence in hemodialysis patients: current perspectives Umeukeje, Ebele M Mixon, Amanda S Cavanaugh, Kerri L Patient Prefer Adherence Review OBJECTIVES: This review summarizes factors relevant for adherence to phosphate-control strategies in dialysis patients, and discusses interventions to overcome related challenges. METHODS: A literature search including the terms “phosphorus”, “phosphorus control”, “hemo-dialysis”, “phosphate binder medications”, “phosphorus diet”, “adherence”, and “nonadherence” was undertaken using PubMed, PsycInfo, CINAHL, and Embase. RESULTS: Hyperphosphatemia is associated with cardiovascular and all-cause mortality in dialysis patients. Management of hyperphosphatemia depends on phosphate binder medication therapy, a low-phosphorus diet, and dialysis. Phosphate binder therapy is associated with a survival benefit. Dietary restriction is complex because of the need to maintain adequate protein intake and, alone, is insufficient for phosphorus control. Similarly, conventional hemodialysis alone is insufficient for phosphorus control due to the kinetics of dialytic phosphorus removal. Thus, all three treatment approaches are important contributors, with dietary restriction and dialysis as adjuncts to the requisite phosphate binder therapy. Phosphate-control adherence rates are suboptimal and are influenced directly by patient, provider, and phosphorus-control strategy-related factors. Psychosocial factors have been implicated as influential “drivers” of adherence behaviors in dialysis patients, and factors based on self-motivation associate directly with adherence behavior. Higher-risk subgroups of nonadherent patients include younger dialysis patients and non-whites. Provider attitudes may be important – yet unaddressed – determinants of adherence behaviors of dialysis patients. CONCLUSION: Adherence to phosphate binders, low-phosphorus diet, and dialysis prescription is suboptimal. Multicomponent strategies that concurrently address therapy-related factors such as side effects, patient factors targeting self-motivation, and provider factors to improve attitudes and delivery of culturally sensitive care show the most promise for long-term control of phosphorus levels. Moreover, it will be important to identify patients at highest risk for lack of control, and for programs to be ready to deliver flexible person-centered strategies through training and dedicated resources to align with the needs of all patients. Dove Medical Press 2018-07-04 /pmc/articles/PMC6039061/ /pubmed/30013329 http://dx.doi.org/10.2147/PPA.S145648 Text en © 2018 Umeukeje et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Umeukeje, Ebele M
Mixon, Amanda S
Cavanaugh, Kerri L
Phosphate-control adherence in hemodialysis patients: current perspectives
title Phosphate-control adherence in hemodialysis patients: current perspectives
title_full Phosphate-control adherence in hemodialysis patients: current perspectives
title_fullStr Phosphate-control adherence in hemodialysis patients: current perspectives
title_full_unstemmed Phosphate-control adherence in hemodialysis patients: current perspectives
title_short Phosphate-control adherence in hemodialysis patients: current perspectives
title_sort phosphate-control adherence in hemodialysis patients: current perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039061/
https://www.ncbi.nlm.nih.gov/pubmed/30013329
http://dx.doi.org/10.2147/PPA.S145648
work_keys_str_mv AT umeukejeebelem phosphatecontroladherenceinhemodialysispatientscurrentperspectives
AT mixonamandas phosphatecontroladherenceinhemodialysispatientscurrentperspectives
AT cavanaughkerril phosphatecontroladherenceinhemodialysispatientscurrentperspectives